What Селинкро Treats: Main Uses and Benefits

This medication is primarily used in the therapeutic domain of Alcohol Use Disorder (AUD) in adults, specifically for established alcohol dependence. It is applied across domains where additional symptomatic support is needed to address chronic, high-risk consumption patterns. The medication is commonly used to help with symptom clusters that interfere with daily functioning, such as the intense, compulsive urge to consume (craving) and difficulty limiting the amount consumed.

The core indication helps patients in the management of high-risk drinking levels and is relevant for easing problematic consumption. This supports the patient during difficult episodes by contributing to easing the overall symptom load and contributes to improved comfort during periods of heightened symptoms. The medication provides supportive relief when symptoms interfere with routine activities.

It is applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.

---

Quick Fact: Relief for Compulsive Urge
Primary Indication	Alcohol Use Disorder (AUD) / Alcohol Dependence
Symptom Targeted	Symptom clusters that interfere with daily functioning, such as the intense, compulsive urge to consume
Benefit	May assist with maintaining functional stability and supports easing problematic consumption

---

Regulatory References

1. European Medicines Agency (EMA) overview

Who can and cannot use Селинкро?

The eligibility for using Nalmefene is strictly defined by regulatory documents based on patient population and pre-existing conditions. The medicine is indicated only for adult patients (aged 18 years and older) who have diagnosed alcohol dependence, maintain a high drinking risk level, and are currently without physical alcohol withdrawal symptoms and do not require immediate detoxification. Treatment must be initiated in conjunction with continuous psychosocial support.

---

Population Status	Official Regulatory Classification
Contraindicated	Use is absolutely prohibited for patients with severe hepatic or severe renal impairment, those with a recent history of acute alcohol withdrawal syndrome, or those with opioid addiction or taking opioid medicines.
Use Not Established	Safety and efficacy are not established in children and adolescents (under 18 years). Use is not recommended during pregnancy.
Caution Advised	Caution should be exercised in older adults (aged 65 years and older) due to limited clinical data, and in patients with mild or moderate hepatic or renal impairment, which requires more frequent monitoring.

---

Interaction Map: Interactions with other medicines and products — official regulatory information for Селинкро (Nalmefene)

Interaction scope

Classification	Categories and Examples
Medicinal product categories with documented interactions	Opioid Agonists, Partial Opioid Agonists, CNS Depressants, Potent UGT2B7 Inhibitors, UGT Inducers.
Specific interacting medicines (if explicitly listed)	Diclofenac, Fluconazole (UGT2B7 Inhibitors); Omeprazole, Rifampicin (UGT Inducers); Methadone, Buprenorphine (Opioids).
Mechanistic basis of interactions (only if stated in label)	Opioid Receptor Antagonism (Pharmacodynamic); Inhibition/Induction of the UGT2B7 enzyme (Pharmacokinetic, altering clearance).

Timing-based and Population-specific Constraints

Constraint Type	Regulatory Statement
Timing-based interaction rules	Temporary discontinuation for 1 week prior to the anticipated use of opioids, such as for elective surgery requiring opioid analgesia.
Population-specific interaction notes	Severe hepatic impairment (Child-Pugh C) and severe renal impairment (eGFR < 30 mL/min per 1.73 m²) are formal contraindications due to increased exposure risk. Caution is advised for mild or moderate impairment.

Interaction-related restrictions

Restriction Type	Official Regulatory Statement
Contraindicated Combinations	Co-administration with opioid agonists (including opioid analgesics) is contraindicated, posing a risk of precipitating acute opioid withdrawal syndrome.
Exposure-Modifying Substances	Potent UGT2B7 inhibitors may significantly increase Nalmefene plasma levels, while UGT inducers may potentially lead to subtherapeutic levels.
Alcohol/Food	No clinically relevant pharmacokinetic interaction exists with alcohol. The official regulatory data states a high-fat meal increases exposure but is unlikely to be of clinical relevance.

Connection to the overall interaction profile: The regulatory documents establish Nalmefene's interaction profile based on two primary mechanisms: Opioid Receptor Antagonism, which mandates formal contraindication with opioid agonists and a required timing separation rule; and UGT2B7 enzyme metabolism, which dictates exposure-modifying restrictions with specific inhibitor and inducer substances. These constraints define the required conditions for safe co-administration and the necessary restrictions within populations with impaired clearance.

Nalmefene is an opioid system modulator that acts on the neurochemical signaling within the mesolimbic pathway. The mechanism involves a dual-action binding profile across three opioid receptor subtypes, resulting in the attenuation of signaling within the mesolimbic reinforcement pathway.

Nalmefene acts as a competitive antagonist at the mu (Mu) and delta (Delta) opioid receptors, while simultaneously acting as a partial agonist at the kappa (Kappa) opioid receptor. This receptor profile establishes a modulatory presence at the key signaling junctions that govern positive reinforcement. Mechanistically, Nalmefene achieves high receptor occupancy, which is necessary to achieve the functional blockade of the target receptors.

The drug's antagonism blocks the binding of endogenous opioids (released following ethanol consumption) to the mu and delta receptors within the Cortico-mesolimbic Pathway. This prevents the subsequent release of dopamine in the nucleus accumbens, which is the physiological basis for the subsequent reinforcement signaling. The physiological consequence of this blockade is a downstream attenuation of the reward signal, which correlates with a decrease in the reinforcement signaling of the mesolimbic pathway.

How to use Селинкро: Official Administration Guidelines

Селинкро (nalmefene 18 mg film-coated tablets) is administered orally following a highly specified, event-driven dosing schedule.

Field	Instruction
Route of administration	Oral use
Dosing schedule	One single 18 mg film-coated tablet per day.
Timing in relation to meals	May be taken with or without food.
Preparation requirements	The tablet must be swallowed whole and must not be divided or crushed.
Age-group administration rules	Older Adults (≥65 years): No dose adjustment is generally recommended. Pediatric Patients (<18 years): Use is not recommended.
Missed-dose rules	If a dose is missed (no drinking occurred), the next dose is taken before the next anticipated drinking episode.
Special procedural conditions	The dose must be taken 1–2 hours prior to the anticipated time of drinking.

---

Frequency and Use Context

The administration follows an as-needed frequency pattern, which is entirely dependent on the patient's perceived risk of consuming alcohol on any given day. This protocol defines the usage as intermittent, distinguishing it from continuous daily dosing regimens. Treatment is used in conjunction with continuous psychosocial support. The overall protocol ensures the medication is used strictly according to the approved event-driven pattern, with the necessity for continued treatment being subject to regular review.

Research evidence / Overview of studies for Селинкро (Nalmefene)

---

Evidence for Use in Reducing Alcohol Consumption

Research on Селинкро has primarily been conducted using Randomized Controlled Trials (RCTs), a study design used by regulators to evaluate medicines. In these studies, patients was observed in groups receiving either the medicine or a placebo (an inactive tablet) to compare observed patterns under controlled conditions. This research focused specifically on adult patients diagnosed with alcohol dependence who were assessed as having a high level of risk associated with their drinking at the start of the study. Research explored the use of the drug in settings where patients also received psychosocial support.

Research so far describes patterns of change in the number of heavy drinking days and the overall alcohol consumption that were measured in the nalmefene group compared to the placebo group within the typical six-month study period. However, when regulatory bodies and reviewers assessed these findings, uncertainty remains regarding the size of these measured changes and their clinical meaning. This means that while changes were observed, the findings help contextualize how patients reported their experience.

---

Study Outcomes and Measures Examined

Beyond tracking how much alcohol was observed in the study population, studies also monitored other outcomes reflecting daily functioning or activity level. Researchers used tools like the Clinical Global Impression (CGI) scores to assess investigator-rated changes in global severity and symptom patterns. Studies also examined changes in biomarkers, which are biological indicators in the body. Specifically, research included monitoring liver enzyme levels, such as Gamma-Glutamyl Transferase (gamma-GT) and Alanine Aminotransferase (ALT), which were monitored in the studies.

---

Long-Term Studies and Follow-Up

Most of the primary evidence for how nalmefene was evaluated in consumption patterns was collected over defined time intervals of about 6 months (24 weeks). Longer-term research, including follow-up for up to 12 months (52 weeks) in the main trials and up to 18 months in some post-authorisation observational settings, focused on monitoring safety and secondary outcomes.

However, the long-term durability of the measured outcomes is not fully established. There is limited information for long-term outcomes regarding the durability of the consumption changes or the patient's persistence in using the medicine beyond one year. The available evidence contributes to understanding symptom patterns over the intermediate term but it is not yet clear on outcomes beyond that timeframe.

Key Studies & References

1. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials

Common questions about Селинкро (FAQ)

---

Q: How quickly should someone expect to see an effect from Селинкро?

Official regulatory documents indicate that the active substance in Селинкро is rapidly absorbed after being taken orally. The substance is described in official documents as reaching its highest concentration in the bloodstream in approximately 1.5 hours after a dose. Studies focusing on receptor binding show that the high level of occupancy needed for action is achieved within approximately 3 hours after a dose.

---

Q: What happens if I forget to take a dose of Селинкро?

Since Селинкро is taken only before an anticipated drinking episode, if drinking has already begun without a dose, the administration rules state that one tablet should be taken as soon as possible on that day. It is important to remember that the total dose must remain at a maximum of one tablet per day.

---

Q: Is Селинкро used to help stop drinking completely, or to cut down?

The official indication for Селинкро is to support the reduction of alcohol consumption in adults diagnosed with alcohol dependence and a high risk of drinking. The medicine is intended to assist a person's effort to diminish the overall frequency and amount of alcohol consumed, rather than aiming for immediate total abstinence.

---

Q: Does Селинкро cause weight gain or weight loss?

Based on clinical data, a decreased appetite is listed as a common side effect of Селинкро. Official regulatory documents also list weight decreased as an uncommon adverse reaction. There is no information in the adverse reaction profile indicating that the medication commonly causes weight gain.

---

Q: Can Селинкро be taken with common pain relievers like ibuprofen or paracetamol?

Official restrictions state that the use of opioid analgesics is formally contraindicated. While non-opioid pain relievers like ibuprofen and paracetamol are not specifically named as having an interaction, certain strong enzyme inhibitors may affect the drug's levels. No clinically significant interactions are generally expected with most medicines that use common metabolic pathways.

---

Q: What happens if I take more than the recommended dose of Селинкро?

The maximum recommended dose is one tablet per day. The full details regarding the consequences of acute overdose are limited. Official documents note that high exposure, such as taking more than the daily maximum, is associated with increased adverse reactions.

---

Q: How does Селинкро affect sleep patterns?

Official safety data lists insomnia (difficulty sleeping) as a very common adverse reaction. Other related side effects that may affect sleep include somnolence (drowsiness) and nightmare, which are listed as common reactions.

---

Q: Is it safe to use Селинкро if I'm taking antidepressants?

Antidepressants are not formally listed as contraindicated. However, official product information suggests that co-administration with other medicines that act as CNS depressants (which slow brain activity) requires consideration due to potential additive effects. Caution regarding certain enzyme modulators is also mentioned.

---

Q: Is it possible to become dependent on Селинкро?

Селинкро is classified as an opioid receptor antagonist (a blocker/modulator). Based on its pharmacological class and clinical studies, the medicine is described as having no known potential for physical dependence, drug tolerance, or abuse. This is because it does not have the same type of activity as medicines associated with addiction.

---

Q: What is the difference between Селинкро and naltrexone?

Both medicines belong to the pharmacological class of opioid receptor antagonists. Official pharmacology notes that Селинкро (nalmefene) is structurally related to naltrexone but has a different profile. Key differences described include Селинкро's longer half-life and its unique, distinct binding profile across the mu, delta, and kappa opioid receptors.

---

Q: Can older people (senior citizens) use Селинкро?

Regulatory documents indicate that people aged 65 years and older can generally use Селинкро without a mandatory dose adjustment based on age alone. However, official information states that caution should be exercised when considering use in this age group because there is limited specific clinical data available.

---

Q: Are there specific food restrictions when using Селинкро?

No specific food restrictions are mandated. Official regulatory information states that the tablet may be taken with or without food. While taking it with a high-fat meal can slightly increase the drug's levels in the body, this change is not generally considered to be clinically important.

---

Q: Does Селинкро work for everyone who takes it?

Clinical trials observed that patients taking Селинкро, when receiving psychosocial support, had reductions in heavy drinking days and total alcohol consumption compared to the placebo group. However, evidence summaries note that uncertainty remains about the exact size of the measured benefits and their meaning for every individual.

---

Q: Does taking Селинкро mean I need to attend therapy sessions?

Yes, according to the official regulatory approval, Селинкро must only be prescribed when it is used in conjunction with continuous psychosocial support. This support is meant to focus on helping the patient adhere to the treatment and achieve their goal of reducing alcohol consumption.

How to Store and Dispose of Selincro (Nalmefene)

Official Storage Requirements

Selincro film-coated tablets do not require any special precautions for storage and are stable under general conditions. The labeled shelf life for the product is 3 years.

Crucially, the medication must be kept out of the sight and reach of children.

Handling and Protection

The film-coated tablet should be swallowed whole and must not be divided or crushed. This is a mandatory handling rule because the active substance, nalmefene, may cause skin sensitisation upon direct contact. The tablets are supplied in their original blister packaging.

Disposal Instructions

Any unused medicinal product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste, as directed by regulatory bodies.